Aduro Biotech is an immunotherapy company focused on the discovery, development and commercialization of therapies for the treatment of patients with diseases, including cancer. Co.'s primary technologies related to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand pathways have a pipeline of clinical candidates including ADU-S100 (MIW815), ADU-S100 with spartalizumab, ADU-S100 with ipilimumab, ADU-S100 with anti-PD-1, cGAS-STING pathway inhibitor program, and BION-1301. Co.'s other programs consist of Anti-CD27 Antibody, which is a co-stimulatory receptor expressed on different immune cells, such as T-lymphocytes and NK cells. We show 20 historical shares outstanding datapoints in our coverage of ADRO's shares outstanding history.
Understanding the changing numbers of ADRO shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ADRO versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ADRO by allowing them to research ADRO shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
